How did ENZ's earnings surprise investors in Q2 2025?

Enzo Biochem's Q2 2025 earnings did not surprise investors, as the company's earnings report for the period has not been released. However, the company's data breach settlement and its impact on investors' expectations may be a significant factor to consider. 1. **Data Breach Settlement**: Enzo Biochem was involved in a data breach in 2023, which potentially compromised patient information. The company reached a $7.5 million settlement to resolve claims related to this data breach. This settlement is part of a class action lawsuit against Enzo Biochem, accusing the company of not implementing proper cybersecurity measures. 2. **Investor Expectations**: The data breach and subsequent settlement may have influenced investors' expectations for Enzo Biochem's earnings in Q2 2025. The company's failure to adequately protect patient data could have led to increased expenses related to legal fees, cybersecurity enhancements, and potential claims for damages. These factors could have impacted Enzo Biochem's financial performance, potentially leading to lower-than-expected earnings. 3. **Stock Performance**: Enzo Biochem's stock experienced a decrease of 7.1% on the NYSE in Q2 2025, which may reflect investors' reactions to the data breach and settlement news. The stock's performance could be an indicator of how investors perceived the company's financial health and future prospects following the data breach. In conclusion, while Enzo Biochem's Q2 2025 earnings report has not been released, the company's data breach settlement and its implications for increased expenses and reputational damage may have contributed to lower-than-expected earnings. The stock's performance during the quarter also suggests that investors were concerned about the company's financial health and future prospects following the data breach.